☰

Alexander W. Hird, Ph.D. - Publications

Affiliations: 
2006 Boston College, Newton, MA, United States 
Area:
catalysts
Tree Info Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Maia de Oliveira T, Korboukh V, Caswell S, Winter Holt JJ, Lamb M, Hird AW, Overman R. The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif. The Biochemical Journal. 477: 275-284. PMID 31868900 DOI: 10.1042/Bcj20190196  0.303
2019 Yang B, Hird AW, Bodnarchuk MS, Zheng X, Dakin L, Su Q, Daly K, Godin R, Hattersley MM, Brassil P, Redmond S, John Russell D, Janetka JW. Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254). Bioorganic & Medicinal Chemistry. 115227. PMID 31862310 DOI: 10.1016/J.Bmc.2019.115227  0.353
2019 Balazs AYS, Carbajo RJ, Davies NL, Dong Y, Hird AW, Johannes JW, Lamb ML, McCoull W, Raubo P, Robb GR, Packer MJ, Chiarparin E. Free Ligand 1D NMR Conformational Signatures to Enhance Structure Based Drug Design of a Mcl-1 inhibitor (AZD5991) and other Synthetic Macrocycles. Journal of Medicinal Chemistry. PMID 31361481 DOI: 10.1021/Acs.Jmedchem.9B00716  0.348
2019 Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacology & Therapeutics. PMID 30790641 DOI: 10.1016/J.Pharmthera.2019.02.007  0.314
2018 Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, ... ... Hird AW, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications. 9: 5341. PMID 30559424 DOI: 10.1038/S41467-018-07551-W  0.331
2018 Yang B, Vasbinder M, Hird AW, Su Q, Wang H, Yu Y, Toader D, Lyne PD, Read JA, Breed J, Ioannidis S, Deng C, Grondine M, DeGrace N, Whitston D, et al. Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. Journal of Medicinal Chemistry. PMID 29301085 DOI: 10.1021/Acs.Jmedchem.7B01490  0.35
2018 Tron AE, Belmonte MA, Criscione S, Clark EA, Gangl E, Gibbons FD, Tyner JW, Kurtz SE, Ye Q, Hird AW, Schuller A, Secrist JP. Abstract 302: Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves antitumor activity in multiple myeloma and acute myeloid leukemia Cancer Research. 78: 302-302. DOI: 10.1158/1538-7445.Am2018-302  0.34
2018 Barlaam B, Savi CD, Drew L, Ferguson AD, Ferguson D, Gu C, Hawkins J, Hird AW, Lamb ML, O'Connell N, Pike K, Proia T, Martin MS, Vasbinder MM, Varnes J, et al. Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies Cancer Research. 78: 1650-1650. DOI: 10.1158/1538-7445.Am2018-1650  0.353
2017 Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, ... ... Hird AW, et al. Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors". Acs Medicinal Chemistry Letters. 8: 1204. PMID 29152055 DOI: 10.1021/Acsmedchemlett.7B00397  0.303
2017 Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, ... ... Hird AW, et al. Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. Acs Medicinal Chemistry Letters. 8: 239-244. PMID 28197319 DOI: 10.1021/Acsmedchemlett.6B00464  0.381
2017 Hird AW, Secrist JP, Adam A, Belmonte MA, Gangl E, Gibbons F, Hargreaves D, Johannes JW, Kazmirski SL, Kettle JG, Kurtz SE, Lamb ML, Packer MJ, Peng B, Stewart CR, et al. Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ddt01-02  0.334
2016 Akçay G, Belmonte MA, Aquila B, Chuaqui C, Hird AW, Lamb ML, Rawlins PB, Su N, Tentarelli S, Grimster NP, Su Q. Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain. Nature Chemical Biology. PMID 27595327 DOI: 10.1038/Nchembio.2174  0.308
2016 Varnes JG, McGuire T, Meadows RE, Barlaam B, Clark J, Cook CR, Davison G, Dishington A, De Savi C, Donald C, Grebe T, Hande S, Hawkins J, Hird AW, Holmes J, et al. General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles Tetrahedron Letters. 57: 4718-4722. DOI: 10.1016/J.Tetlet.2016.09.029  0.418
2015 Su Q, Akçay G, Grimster N, Belmonte M, Rawlins P, Lamb M, Hird A, Aquila B. Abstract C40: Inhibition of Mcl-1 through covalent modification of a non-catalytic lysine side chain Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C40  0.365
2014 Hird AW, Aquila BM, Block MH, Hennessy EJ, Kamhi VM, Omer CA, Laing NM, Saeh JC, Sha L, Yang B. Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 1820-4. PMID 24631189 DOI: 10.1016/J.Bmcl.2014.02.016  0.416
2014 Belmonte MA, Adam A, Borrelli D, Bhavsar D, Bebernitz C, Hird A, Secrist P. Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma Blood. 124: 3428-3428. DOI: 10.1182/Blood.V124.21.3428.3428  0.323
2013 Dowling JE, Alimzhanov M, Bao L, Block MH, Chuaqui C, Cooke EL, Denz CR, Hird A, Huang S, Larsen NA, Peng B, Pontz TW, Rivard-Costa C, Saeh JC, Thakur K, et al. Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. Acs Medicinal Chemistry Letters. 4: 800-5. PMID 24900749 DOI: 10.1021/Ml400197U  0.362
2013 Hennessy EJ, Adam A, Aquila BM, Castriotta LM, Cook D, Hattersley M, Hird AW, Huntington C, Kamhi VM, Laing NM, Li D, MacIntyre T, Omer CA, Oza V, Patterson T, et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). Journal of Medicinal Chemistry. 56: 9897-919. PMID 24320998 DOI: 10.1021/Jm401075X  0.331
2013 Lamb ML, Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Huszar D, Keeton EK, Lyne PD, Pollard H, et al. Abstract 2353: Novel inhibitors of PIM-1, PIM-2, and PIM-3 protein kinases: medicinal chemistry leading to AZD1208. Cancer Research. 73: 2353-2353. DOI: 10.1158/1538-7445.Am2013-2353  0.348
2013 Saeh JC, Aquila B, Russell D, Hennessy E, Hird A, Vasbinder M, Ferguson A, Yang B, Hattersley M, Laing N, MacIntyre T, Patterson T, Repik G, Rooney M, Wang H, et al. Abstract B100: Structure-based design of AZ7732 a novel in vivo active beta-alanine-derived pan-IAP inhibitor. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B100  0.37
2012 Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK, Lamb ML, Lyne PD, Pollard H, Read J, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorganic & Medicinal Chemistry Letters. 22: 4599-604. PMID 22727640 DOI: 10.1016/J.Bmcl.2012.05.098  0.343
2012 Yang B, Hird AW, Russell DJ, Fauber BP, Dakin LA, Zheng X, Su Q, Godin R, Brassil P, Devereaux E, Janetka JW. Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO Bioorganic and Medicinal Chemistry Letters. 22: 4907-4911. PMID 22704236 DOI: 10.1016/J.Bmcl.2012.04.104  0.343
2006 Lee KS, Brown MK, Hird AW, Hoveyda AH. A practical method for enantioselective synthesis of all-carbon quaternary stereogenic centers through NHC-Cu-catalyzed conjugate additions of alkyl- and arylzinc reagents to beta-substituted cyclic enones. Journal of the American Chemical Society. 128: 7182-4. PMID 16734469 DOI: 10.1021/Ja062061O  0.64
2006 Takle AK, Brown MJ, Davies S, Dean DK, Francis G, Gaiba A, Hird AW, King FD, Lovell PJ, Naylor A, Reith AD, Steadman JG, Wilson DM. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorganic & Medicinal Chemistry Letters. 16: 378-81. PMID 16260133 DOI: 10.1016/J.Bmcl.2005.09.072  0.305
2006 Hoveyda A, Lee K, Brown M, Hird A. Enantioselective Conjugate Addition of Organozinc Reagents to Enones Synfacts. 2006: 0913-0913. DOI: 10.1055/S-2006-949261  0.568
2005 Hird AW, Hoveyda AH. Catalytic enantioselective alkylations of tetrasubstituted olefins. Synthesis of all-carbon quaternary stereogenic centers through Cu-catalyzed asymmetric conjugate additions of alkylzinc reagents to enones. Journal of the American Chemical Society. 127: 14988-9. PMID 16248613 DOI: 10.1021/Ja0553811  0.61
2004 Hoveyda AH, Hird AW, Kacprzynski MA. Small peptides as ligands for catalytic asymmetric alkylations of olefins. Rational design of catalysts or of searches that lead to them? Chemical Communications (Cambridge, England). 1779-85. PMID 15306882 DOI: 10.1039/B401123F  0.508
2003 Hird AW, Hoveyda AH. Cu-catalyzed enantioselective conjugate additions of alkyl zinc reagents to unsaturated N-acyloxazolidinones promoted by a chiral triamide phosphane. Angewandte Chemie (International Ed. in English). 42: 1276-9. PMID 12645063 DOI: 10.1002/Anie.200390328  0.567
Show low-probability matches.